Reference number : GC-2017-Q4-00043, amendment number : , agreement type : G, recipient legal name : Allen, Christine (University of Toronto), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Collaborative Research and Development Grants - Project, program name french : Subventions de recherche et développement coopérative - projet, program purpose english : There are currently more than 20 pharmaceutical products that include implantable, insertable or injectable_x000D_
drug delivery systems that are formed from the copolymer poly(lactide-co-glycolide) (PLGA) and provide_x000D_
sustained release of drug therapy over time. The sustained drug release that is achieved with a single_x000D_
administration, eliminates the need for daily or weekly drug administrations and as a result has a profoundly_x000D_
positive impact on a patient's quality of life, patient compliance and leads to significant reductions in health_x000D_
care costs. These products are currently used to treat critical medical conditions including diabetes,_x000D_
endometriosis, prostate cancer and schizophrenia. While PLGA-based systems have provided a delivery_x000D_
solution to many drugs, it is clear, a new polymeric delivery system is needed to meet the needs of the_x000D_
pharmaceutical industry. Given that each drug is unique in terms of its physico-chemical properties and that_x000D_
polymer-drug interaction and compatibility are key metrics that influence the performance of polymeric_x000D_
delivery formulations there is no single polymer that can serve as a universal material for formulation of all_x000D_
drugs. For this reason, Pendant Biosciences (a Canadian company) has patented, and in collaboration with the_x000D_
Allen laboratory filed an additional provisional patent application, on a flexible polymer platform that includes_x000D_
recognized building blocks that produce cross-linked biocompatible systems for prolonged delivery of a wide_x000D_
range of drugs. If successful, the proposed research will result in (1) identification of a lead drug-polymer_x000D_
product for development by Pendant Biosciences; (2) a 'tool-box' of biocompatible polymer materials to_x000D_
facilitate drug-delivery research in academic and industrial settings and (3) increased scientific awareness of_x000D_
the physical and chemical metrics responsible for the performance of a drug-polymer combination product., program purpose french : There are currently more than 20 pharmaceutical products that include implantable, insertable or injectable_x000D_
drug delivery systems that are formed from the copolymer poly(lactide-co-glycolide) (PLGA) and provide_x000D_
sustained release of drug therapy over time. The sustained drug release that is achieved with a single_x000D_
administration, eliminates the need for daily or weekly drug administrations and as a result has a profoundly_x000D_
positive impact on a patient's quality of life, patient compliance and leads to significant reductions in health_x000D_
care costs. These products are currently used to treat critical medical conditions including diabetes,_x000D_
endometriosis, prostate cancer and schizophrenia. While PLGA-based systems have provided a delivery_x000D_
solution to many drugs, it is clear, a new polymeric delivery system is needed to meet the needs of the_x000D_
pharmaceutical industry. Given that each drug is unique in terms of its physico-chemical properties and that_x000D_
polymer-drug interaction and compatibility are key metrics that influence the performance of polymeric_x000D_
delivery formulations there is no single polymer that can serve as a universal material for formulation of all_x000D_
drugs. For this reason, Pendant Biosciences (a Canadian company) has patented, and in collaboration with the_x000D_
Allen laboratory filed an additional provisional patent application, on a flexible polymer platform that includes_x000D_
recognized building blocks that produce cross-linked biocompatible systems for prolonged delivery of a wide_x000D_
range of drugs. If successful, the proposed research will result in (1) identification of a lead drug-polymer_x000D_
product for development by Pendant Biosciences; (2) a 'tool-box' of biocompatible polymer materials to_x000D_
facilitate drug-delivery research in academic and industrial settings and (3) increased scientific awareness of_x000D_
the physical and chemical metrics responsible for the performance of a drug-polymer combination product., agreement title english : Cross-linked polyester-based depot systems for sustained drug delivery: determining the relationship between composition, properties and performance, agreement title french : Cross-linked polyester-based depot systems for sustained drug delivery: determining the relationship between composition, properties and performance, agreement number : CRDPJ, agreement value : 411627.0, agreement start date : 2018-02-07, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2020-2021)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2020-2021)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada